Why the study?
Does early rhythm-control therapy reduce adverse cardiovascular outcomes in patients with early atrial fibrillation and cardiovascular conditions?
Does early rhythm-control therapy reduce adverse cardiovascular outcomes in patients with early atrial fibrillation and cardiovascular conditions?
Early rhythm-control therapy is associated with improved cardiovascular outcomes compared to usual care in patients with early atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports early rhythm-control in early AF with CV conditions; challenges prior low-certainty evidence against benefit.
Early rhythm-control therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care among patients with early atrial fibrillation and cardiovascular conditions. (Funded by the German Ministry of Education and Research and others; EAST-AFNET 4 ISRCTN number, ISRCTN04708680; ClinicalTrials.gov number, NCT01288352; EudraCT number, 2010-021258-20.).
No takes yet. Share an insight, caveat, or question.
Kirchhof et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: